J. Goldman & CO LP Lipocine Inc. Transaction History

J. Goldman & CO LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 14, 2019	SELL	$1.46 - $2.33 $348,104 - $555,537	-238,428 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$1.07 - $1.63 $280,568 - $427,408	-262,214 Reduced 52.38%	238,428 $310,000
Q3 2018 Nov 14, 2018	SELL	$1.31 - $1.63 $280,808 - $349,403	-214,358 Reduced 29.98%	500,642 $691,000
Q2 2018 Aug 14, 2018	BUY	$1.06 - $1.78 $757,900 - $1.27 Million	715,000 New	715,000 $930,000

Ticker LPCN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 88,510,800
Market Cap $290M
Description
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone rep...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.